Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to $58.8 million.

  • C4 Therapeutics' Cash & Equivalents fell 1.41% to $58.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.8 million, marking a year-over-year decrease of 1.41%. This contributed to the annual value of $55.5 million for FY2024, which is 56.16% down from last year.
  • C4 Therapeutics' Cash & Equivalents amounted to $58.8 million in Q3 2025, which was down 24.76% from $78.2 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Cash & Equivalents ranged from a high of $281.1 million in Q2 2021 and a low of $29.8 million during Q4 2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $59.6 million (2024), whereas its average is $68.0 million.
  • Per our database at Business Quant, C4 Therapeutics' Cash & Equivalents tumbled by 79.62% in 2022 and then surged by 325.46% in 2023.
  • Over the past 5 years, C4 Therapeutics' Cash & Equivalents (Quarterly) stood at $76.1 million in 2021, then slumped by 60.91% to $29.8 million in 2022, then skyrocketed by 325.46% to $126.6 million in 2023, then tumbled by 56.16% to $55.5 million in 2024, then dropped by 1.41% to $58.8 million in 2025.
  • Its Cash & Equivalents stands at $58.8 million for Q3 2025, versus $78.2 million for Q2 2025 and $51.3 million for Q1 2025.